PLGA-PEG-N3 and PLGA-PEG-NHS from PolySciTech used in development of cancer-targeted nanoparticle system

 

Antibody’s references a class of biochemicals which have the ability to attach to a specific antigen and the use of antibody-antigen conjugation allows for the development of cancer-targeted nanoparticles. Recently, researchers at Queen's University Belfast and University College London (United Kingdom) used PLGA-PEG-N3 (AI085) and PLGA-PEG-NHS (AI064) from PolySciTech (www.polyscitech.com) to create labelled nanoparticles for delivery to cancer. This research holds promise to improve chemotherapeutic efficacy in the future. Read More: Greene, Michelle, João CF Nogueira, Shannon R. Tracey, Daniel A. Richards, William McDaid, James F. Burrows, Katrina Campbell, Dan Longley, Vijay Chudasama, and Christopher J. Scott. "Refined construction of antibody-targeted nanoparticles leads to superior antigen binding and enhanced delivery of an entrapped payload to pancreatic cancer cells." Nanoscale (2020). https://pubs.rsc.org/en/content/articlehtml/2020/nr/d0nr02387f


“Antibody-targeted nanoparticles have shown exceptional promise as delivery vehicles for anticancer drugs, although manufacturability challenges have hampered clinical progress. These include the potential for uncontrolled and random antibody conjugation, resulting in masked or inactive paratopes and unwanted Fc domain interactions. To circumvent these issues, we show that the interchain disulfide of cetuximab F(ab) may be selectively re-bridged with a strained alkyne handle, to permit ‘click’ coupling to azide-capped nanoparticles in a highly uniform and oriented manner. When compared to conventional carbodiimide chemistry, this conjugation approach leads to the generation of nanoparticles with a higher surface loading of cetuximab F(ab) and with markedly improved ability to bind to the target epidermal growth factor receptor. Moreover, we show that entrapment of a camptothecin payload within these nanoparticles can enhance drug targeting to antigen-expressing pancreatic cancer cells, resulting in superior cytotoxicity versus the conventional nanoformulation. Collectively, this work highlights the critical need to develop refined methods for the construction of targeted nanoparticles that will accelerate their clinical translation through improved performance and manufacturability.”